BFRI
Biofrontera·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
MACD Golden Cross
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BFRI
Biofrontera Inc.
A biopharmaceutical company that develops and commercializes dermatological products
120 Presidential Way, Suite 330, Woburn, MA 01801
--
Biofrontera Inc., was incorporated in Delaware in March 2015. The company is a US-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of skin diseases, especially diseases that cause skin damage due primarily to sun exposure. The company's licensed products focus on the treatment of actinic keratosis, a skin lesion that sometimes leads to skin cancer. The company also sells a topical antibiotic for the treatment of impetigo, a bacterial skin infection.
Earnings Call
Q1/2025
Estimate EPS-0.29
Actual EPS-0.47
Estimate Revenue10.55M
Actual Revenue8.59M
Biofrontera's Q1 2025 Earnings Call: Unpacking Contradictions in Sales Strategy, Gross Margins, and Inventory Management
May 13,2025 11:09
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BFRI has released its 2025 Q3 earnings. EPS was reported at -0.62, versus the expected -0.56, missing expectations. The chart below visualizes how BFRI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BFRI has released its 2025 Q3 earnings report, with revenue of 6.99M, reflecting a YoY change of -22.46%, and net profit of -6.65M, showing a YoY change of -17.29%. The Sankey diagram below clearly presents BFRI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
